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ORIGINAL RESEARCH
Abstract: In schizophrenia, alterations of proinflammatory cytokine levels have been reported
and related to the disease and psychopathology. However, only limited conclusions can be
drawn in view of confounding factors such as infection, age, sex, smoking, and antipsychotic
medication. Chronic schizophrenic patients with a long-term disease process and medication
period have not been investigated so far. We have measured serum levels of interleukin (IL)-
1β, IL-6, and tumor necrosis factor (TNF)α in 41 elderly, chronic schizophrenic patients and
23 age- and sex-matched controls using enzyme-linked immunosorbent assay (ELISA). We
assessed detailed psychopathology and neuropsychological performance and determined serum
levels of haloperidol, clozapine, and the two main clozapine metabolites, desmethylclozapine
and clozapine metabolite N-oxide, by high-pressure liquid chromatography (HPLC). IL-1β
and IL-6 levels were increased in treatment-resistant schizophrenic patients compared with
healthy controls, whereas TNFα showed no difference. We did not find statistically significant
differences of cytokine levels between medication groups and there was no correlation with
serum levels of antipsychotics or psychopathological rating scores. Elevations of IL-1β and
IL-6 in elderly chronic schizophrenic patients may be related to an active disease process
lasting until old age. Despite missing correlations, long-term treatment effects in treatment-
resistant patients may have affected TNFα, leading to control levels. Post-mortem and animal
studies should clarify the presence of altered immune function in the brain as well as the
effect of cytokine levels in relation to neurodevelopmental disturbances and schizophrenia-
associated behavior.
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Introduction
Schizophrenia is a severe psychiatric disorder with positive symptoms such as
hallucinations, thought disorder, and delusions as well as negative symptoms. During
recent decades, evidence for the involvement of the immune system has accumulated.
Schizophrenia has been associated with decreased mitogen-induced lymphocyte
proliferation (Chengappa et al 1995), increased numbers of total T and T-helper cells
(Muller et al 1993), and the presence of antibrain antibodies in serum (Henneberg et
al 1994). However, the pathophysiology of the disease remains elusive.
Cytokines are proteins that modulate systemic and central nervous system (CNS)
responses to infection, inflammation, and injury (Rothwell 1999). They are released
from various blood cells (macrophages, monocytes, T and B cells). In the brain they
are expressed by neurons, astroglia, and microglia and regulate brain development
(Kreutzberg 2000; Vitkovic et al 2000). Proinflammatory cytokines such as interleukin
(IL)-1β, IL-6, and tumor necrosis factor (TNF)α may play an important role in the
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association between prenatal virus infection and
schizophrenia (Nawa et al 2000; Urakubo et al 2001).
Changes in cytokines and cytokine receptors have been
reported in plasma, serum, and cerebrospinal fluid (CSF)
of schizophrenic patients, such as increased IL-6, IL-1β,
and TNFα (Shintani et al 1991; Ganguli et al 1994; Xu et al
1994; Maes et al 1995; Naudin et al 1996; Frommberger et
al 1997; Monteleone et al 1997; Lin et al 1998; van Kammen
et al 1999; Theodoropoulou et al 2001; Zhang et al 2002;
Garver et al 2003). However, results are inconsistent (Baker
et al 1996; Kim et al 1998; Haack et al 1999; Kudoh et al
2001), but several investigations have shown a relationship
between IL-6 and negative symptoms, duration of the disease
(Ganguli et al 1994; Akiyama 1999; Kim et al 2000), acute
state of the disorder (Frommberger et al 1997), and treatment
resistance (Lin et al 1998). These findings suggest that high
IL-6 levels are associated with an unfavorable course of the
disease (Müller et al 2000). On the other hand, IL-6 levels
have been reported to be higher in younger schizophrenic
patients than in older individuals (Maes et al 1994). So far,
hospitalized elderly patients with long-term schizophrenia
and persistent positive and negative symptoms as well as
neurocognitive deficits have not been investigated. We
hypothesize that chronic elderly schizophrenic patients have
elevated serum levels of IL-6, IL-1β, and TNFα compared
with age-matched healthy controls.
However, factors such as age, body mass index, sex,
smoking habits, recent infectious diseases, and medication
have been reported to affect IL-6 levels (Haack et al 1999).
Repeated blood drawings by intravenous catheter, but not
by needle stick, increased local IL-6 levels (Haack et al
2002). In CNS cell cultures, typical neuroleptics such as
phenothiazines inhibited production of IL-6 after stimulation
with polysaccharides (Müller et al 2000). Haloperidol
normalized the increased serum IL-6 levels in acute
schizophrenic patients (Maes et al 1994, 1995, 1997).
Additionally, haloperidol decreased IL-1β and TNFα
released from monocytes (Kowalski et al 2001). In contrast,
clozapine stimulated in vivo release of IL-6 and TNFα
during the first weeks of treatment (Pollmacher et al 1996;
Maes et al 1997; Hinze-Selch et al 2000). After 10 weeks of
clozapine administration, TNFα levels have been reported
to have decreased (Monteleone et al 1997). Regarding
plasma levels of the IL-1β receptor antagonist, there are
conflicting results (Pollmacher et al 1996; Maes et al 1997).
However, long-term effects of typical and atypical
antipsychotic treatment on circulating cytokine levels have
not yet been investigated. In addition, effects of clozapine
metabolites on serum cytokines are unknown. To address
this, we investigated serum IL-1β, IL-6, and TNFα levels,
psychopathological and neuropsychological scores, and
haloperidol, clozapine, and clozapine metabolite levels in
elderly, chronic schizophrenic patients with persisting
symptoms and stable long-term typical neuroleptic and
clozapine treatment.
Methods
Subjects
The study was approved by the Ethics Committee of the
Clinic Mannheim, Heidelberg University. We investigated
41 schizophrenic patients (24 men, 17 women, mean age
63.3 ± 7.0 years) who met the DSM-IV diagnostic criteria
for chronic schizophrenia (APA 1994) and 23 age- and sex-
matched healthy controls (15 men, 8 women, mean age
64.5 ± 9.8 years). Neither the schizophrenic patients nor the
healthy controls suffered from substance or alcohol abuse,
systemic disorders known to be associated with
immunological abnormalities, nor were they receiving
immunosuppressive drugs. This was determined by
anamnesis, clinical examination, and routine blood tests
(including white blood cell differentiation, liver parameters,
electrolytes, and blood sedimentation rate). Twenty-one
schizophrenic patients and six healthy controls were
smokers.
In schizophrenic patients, duration of the illness was
35.3 ± 11.4 years, age at onset was 28.0 ± 10.7 years, and
duration of antipsychotic medication was 27.2 ± 12.3 years.
Mean chlorpromazine equivalents (CPE) at the time of blood
collection were 708.5 ± 591.7 mg/day (Jahn and Mussgay
1989; Meltzer and Fatemi 1998). Fourteen schizophrenic
patients were treated with haloperidol and additive typical
neuroleptics such as perazine, chlorprothixene, thioridazine,
and promethazine (CPE 1302.8 ± 1253.0 mg/day). Fifteen
patients were treated solely with clozapine (CPE
316.5 ± 111.0 mg/day), and eight patients received a
combination of haloperidol, typical neuroleptics, and
clozapine (CPE 585.7 ± 382.3 mg/day).
Psychopathological and
neuropsychological assessments
Dementia in patients and healthy controls was evaluated
using the Mini-Mental State Examination (MMSE) (Folstein
et al 1975). The psychopathological status of schizophrenic
patients was assessed by a trained physician using the Scale
for Assessment of Positive Symptoms (SAPS) (AndreasenNeuropsychiatric Disease and Treatment 2005:1(2) 173
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1983a), the Scale for Assessment of Negative Symptoms
(SANS) (Andreasen 1983b), and the Brief Psychiatric
Rating Scale (BPRS) (Overall and Gorham 1962).
Depressive symptoms were assessed by Hamilton
Depression Rating Scale (HAM-D) (Hamilton 1960).
Cytokine measurements in serum
Sera from patients and controls were collected between 9 am
and 10 am by single needle stick and stored at –80 °C until
thawed for assay. IL-1β, IL-6, and TNFα were measured in
one sample with highly sensitive enzyme-linked
immunosorbent assay (ELISA) kits (R&D Diagnostics,
Wiesbaden, Germany) specific for the human cytokines
according to the manufacturer’s instruction. Cytokine assays
for each patient and his/her matched control were run in the
same lot.
Determination of serum levels of
haloperidol and clozapine
Sample preparation was performed by liquid–liquid
extraction: to 1 mL serum, 2 mL ethyl acetate (supplemented
with 3% ammonium hydroxide) and 40 ng of chlorinated
haloperidol (as internal standard) were added. Samples were
agitated for 30 minutes at 4 °C and then centrifuged at 1850 g
for 15 minutes. The organic supernatant was collected and
concentrated using a SpeedVac-Plus concentrator (SC 110,
Savant, USA). The residue was resolved in 0.2 mL mobile
phase and 80 µL was injected into the chromatograph.
Calibration standards were prepared in serum using
concentrations of 50, 100, 200, 400, 600, and 800 ng/mL
for clozapine and its desmethyl metabolite. Concentrations
of 12.5, 25, 50, 100, 200, and 400 ng/mL for clozapine
N-oxide metabolite and 1.25, 2.5, 5, 10, 20, and 40 ng/mL
for haloperidol were used.
As eluent in high-pressure liquid chromatography
(HPLC), an acetonitrile-ammonium-acetate buffer (80:20%,
v/v) supplemented with 0.83 mmol/L 1-octanesulfonic acid
sodium salt monohydrate was prepared. The pH value was
adjusted to 4.5 using orthophosphoric acid (85%). Isocratic
separation was performed at 1 mL/min and 37 °C. Reversed-
phase HPLC with ion-pair chromatography was performed
with a stainless-steel column (250 mm × 4.6 mm ID) packed
with Hypersil CPS, 5 µm (MZ, Germany). As guard column
the Security-Guard-System (Phenomenex, Germany) was
used. Effluent was monitored at 254 nm with a variable-
wavelength UV detector (Lambda-max, model 481, LC
spectrometer, Waters, Germany). Analysis was performed
using a Dionex instrumentation setting composed of a model
P 580 pump and a GINA 50 autosampler (Dionex,
Germany). Chromatograms were recorded and analyzed
using the Chromeleon integration software (Dionex,
Germany).
All chemicals and drugs were delivered from Sigma-
Aldrich (Germany).
Statistics
Graphical inspection of the data by histograms and results
of Kolmogorov-Smirnov tests showed the non-normal
distribution of the data. Thus, comparisons between
schizophrenic patients and healthy controls as well as
between different treatment groups were carried out by the
nonparametric Mann-Whitney U-test using Bonferroni
correction. Correlations between the variables were analyzed
by Spearman correlation coefficients. Statistical tests were
performed using SPSS 10.0. Results are expressed as
mean ± standard deviation.
Results
Serum IL-1β (p < 0.05) and IL-6 (p < 0.05) levels were
increased in all schizophrenic patients compared with
healthy controls, whereas TNFα showed no difference
(Figure 1). Serum cytokine levels did not differ in smokers
compared with non-smokers. Additionally, cytokine levels
were not different between treatment groups. No significant
correlations have been found between age and cytokine
levels.
In the haloperidol group, mean serum haloperidol level
was 29.3 ± 36.5 ng/mL; in the clozapine group, mean levels
were clozapine 351.3 ± 254.2 ng/mL, desmethylclozapine
182.9 ± 120.7 ng/mL, and the clozapine breakdown product
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Figure 1 Serum interleukin (IL)-6, IL-1β, and tumor necrosis factor (TNF)α in
elderly chronic schizophrenic patients compared with healthy controls. IL-6 and
IL-1β were significantly increased in schizophrenic patients (p < 0.05). Variables
are expressed as mean ± standard deviation.Neuropsychiatric Disease and Treatment 2005:1(2) 174
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N-oxide 143.5 ± 157.1 ng/mL. In the group with combined
medication, mean levels were as follows: haloperidol
25.9 ± 22.8 ng/mL, clozapine 429.9 ± 315.4 ng/mL,
desmethylclozapine 326.9 ± 192.6 ng/mL, and clozapine
metabolite N-oxide 168.2 ± 96.9 ng/mL. IL-6, IL-1β, and
TNFα levels did not correlate with serum haloperidol,
clozapine, desmethylclozapine, or clozapine metabolite
N-oxide levels.
In healthy controls, dementia was excluded, and mean
MMSE score was 29.4 ± 0.6. In schizophrenic patients,
scores were as follows: MMSE 23.8 ± 6, BPRS 46.2 ± 14.9,
SAPS 44.3 ± 27.9, SANS 45.6 ± 22.7, and HAM-D 9.9 ± 6.4.
MMSE and psychopathological scores revealed no
correlations with cytokine levels. In schizophrenic patients,
MMSE scores correlated significantly negatively with levels
of haloperidol (p < 0.05, correlation coefficient –0.616),
clozapine (p < 0.05, correlation coefficient –0.554), and
clozapine metabolite N-oxide (p < 0.05, correlation
coefficient –0.603).
Discussion
This study revealed significant differences in serum levels
of IL-1β and IL-6 in elderly, chronic schizophrenic patients
compared with age- and sex-matched healthy controls. Our
results confirm recent studies reporting increased IL-1β and
IL-6 levels in younger first-episode and chronic
schizophrenic patients (Ganguli et al 1994; Katila et al 1994;
Maes et al 1994, 1995; Naudin et al 1996; Frommberger et
al 1997; Lin et al 1998; Akiyama 1999; van Kammen et al
1999; Theodoropoulou et al 2001; Zhang et al 2002) and
support the hypothesis of disturbed immune function in
schizophrenia lasting until old age. However, the
aforementioned studies differ in methodology (eg, plasma
vs serum), and previous studies did not address age and
medication effects or smoking habits.
Age has been shown to induce increasing activity of the
TNFα and IL-6 system (Haack et al 1999). In contrast, IL-6
levels have been reported to be elevated in younger
schizophrenic patients, but not in patients older than 35 years
(Maes et al 1994). In our study, we did not find a correlation
between age and cytokine levels in elderly schizophrenic
patients or healthy controls, and age did not differ between
groups. Thus, the correlation between age and IL-6 levels
in elderly subjects is questionable. However, only elderly
patients were included in the sample. In order to find a
correlation, a sufficient degree of age variance is necessary,
which may not be present in our selected sample.
In our study, schizophrenic patients had lower MMSE
scores than healthy controls. Thus, differences in cytokine
levels may be affected by coexisting dementia. However,
MMSE scores correlated negatively with serum levels of
antipsychotics and may be influenced by medication effects
such as sedation. Post-mortem studies of plaques, tangles,
and cytokine levels may elucidate the correlation between
dementia and cytokines.
Despite the absence of significant correlations between
psychopathology and cytokine levels, state of the illness
may have an influence on cytokine levels, since all our
patients had a chronic course of the disorder. IL-6 levels
have been reported to be higher during the acute state of the
disease and to decline after remission (Naudin et al 1996;
Frommberger et al 1997). Additionally, elevated IL-1β levels
have been reported in acute but not in chronic schizophrenic
patients (Katila et al 1994). Our study sample consisted of
chronic patients with persisting positive and negative
symptoms as well as neurocognitive deficits. Thus, our
results in chronic patients confirm higher serum IL-6 levels
in treatment-resistant schizophrenic patients than in healthy
controls and patients without treatment resistance (Lin et al
1998). However, in our elderly study group with persisting
symptoms and long-term duration of the disease we did not
investigate treatment resistance. Nor did we confirm
correlations between IL-6 levels and negative symptoms or
correlation with duration of illness measured in younger
schizophrenic patients (Ganguli et al 1994; Kim et al 2001).
Sex-related differences found previously in psychiatric
patients, such as higher TNFα levels in women than in men
(Baker et al 1996) and higher IL-6 levels in males (Ganguli
et al 1994), could not be confirmed by our study. In addition,
we did not find higher IL-6 levels in males than in females.
In accordance with other studies in medicated chronic
schizophrenia (Naudin et al 1996), we did not confirm
elevated TNFα levels in mostly unmedicated schizophrenic
patients compared with healthy controls (Monteleone et al
1997; Theodoropoulou et al 2001).
Although differences have not been detected between
patients on and off neuroleptic medication (Katila et al 1994;
Theodoropoulou et al 2001), treatment effects may have
affected TNFα in our patients, leading to control levels.
Clozapine has been reported to decrease TNFα to normal
levels without effects on IL-6 after a 10-week treatment
period (Monteleone et al 1997). In contrast, short-term
clozapine treatment has been shown to increase TNFα levels
(Pollmacher et al 1996; Hinze-Selch et al 2000).Neuropsychiatric Disease and Treatment 2005:1(2) 175
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Additionally, typical neuroleptics such as haloperidol and
perazine decreased the release of TNFα and IL-1β from
monocytes to control levels (Kowalski et al 2001). Inhibitory
effects of chlorpromazine on TNFα production have also
been observed (Bertini et al 1993). Thus, normal TNFα
levels of schizophrenic patients in our study may be the
consequence of long-term treatment with clozapine and
typical neuroleptics. However, there was no correlation of
serum clozapine, clozapine metabolite, and haloperidol
levels with IL-1β or TNFα. Furthermore, we did not detect
differences in IL-6 and IL-1β levels between treatment
groups, suggesting no specific long-term treatment effects
on these levels. However, in our naturalistic study design,
patients were not treated with haloperidol as monotherapy,
and other typical neuroleptics such as perazine,
chlorprothixene, thioridazine, and promethazine could have
influenced cytokine levels. Thus, additional studies using
monotherapy are warranted.
Clozapine has been shown to increase plasma IL-6 levels
only in vitro and after 2 weeks of treatment, but not during
longer treatment periods (Maes et al 1994, 1997; Hinze-
Selch et al 1998). Thus, clozapine may have short-lasting
immunomodulatory effects that are associated with
clozapine-induced fever and agranulocytosis (Pollmacher
et al 2000). Our results suggest that effects of long-term
clozapine treatment differ from short-term effects. In
contrast, our results confirm previous studies reporting no
effects of haloperidol treatment on IL-6 levels (Kim 1986;
Pollmacher et al 1997). In addition, we did not detect effects
of smoking on proinflammatory cytokines and did not
confirm a study of smoking effects on IL-6 levels (Haack et
al 1999).
Elevated IL-6 plasma and CSF levels have been shown
in patients with autoimmune diseases (Hirano et al 1996)
and inflammation of the CNS (Hirohata et al 1993). Both
IL-1β and IL-6 have been reported to exert an effect on
neuronal growth and differentiation (Giulian et al 1988;
Hama et al 1991). However, it is still controversial whether
peripheral cytokines act in the brain, because cytokines do
not easily cross the blood–brain barrier (Hopkins and
Rothwell 1995; Rothwell and Hopkins 1995). Cytokines
may actively be transported into the brain or may be
produced in the brain itself. They may also act indirectly on
the CNS by activation of endothelial cells and the autonomic
system to stimulate their own synthesis in the brain
(Pollmacher et al 2000). In addition, IL-6 is known to disturb
the blood–brain barrier function (Frei et al 1989).
Polymorphisms in TNFα and IL-1β genes have been
associated with schizophrenia (Boin et al 2001; Schwab et
al 2003; Tan et al 2003; Zanardini et al 2003; Rosa et al
2004) and may contribute to altered protein levels in brain
and periphery and affect brain morphology (Meisenzahl et
al 2001), but results are still contradictory (Tatsumi et al
1997; Riedel et al 2002; Handoko et al 2003; Tsai et al 2003;
Yang et al 2003).
To date, there is only one post-mortem study reporting
decreased gene and protein expression of the IL-1β
inhibiting IL-1 receptor antagonist, but no diagnosis effects
on IL-1β expression in the prefrontal cortex of schizophrenic
patients (Toyooka et al 2003). Since microglia produces
cytokines upon activation (Kreutzberg 2000) and microglial
dysfunction may be involved in the pathophysiology of
schizophrenia (Munn 2000; Radewicz et al 2000), gene and
protein expression studies in post-mortem brains are
warranted to elucidate regulation of cytokines in the CNS.
Expression and signaling of cytokines may be influenced
by environmental factors such as stress, infection, and brain
activity (Nawa et al 2000). A number of environmental
factors have been implicated in schizophrenia, including
hypoxia (Cannon et al 2002; Van Erp et al 2002), maternal
viral infection (Buka et al 2001), nutritional deficiency
(Susser et al 1996), and season of birth (Pulver et al 1981).
All of these could influence cytokine levels.
Proinflammatory cytokines are increased during CNS
ischemia (Saito et al 1996; Orzylowska et al 1999). Season
of birth, however, has no apparent effects on cytokine levels
in schizophrenia (Altamura et al 2003). By contrast, in
keeping with the neurodevelopmental hypothesis, animal
studies revealed schizophrenia-related behavioral
abnormalities such as latent inhibition in adult animals after
immune activation during pregnancy (Zuckerman et al
2003). In embryonic cell culture, IL-1β and IL-6 induced
decreases in the number of neurons immunoreactive for
microtubule-associated protein 2, suggesting decreased
neuronal survival (Marx et al 2001). Moreover, cytokines
are known to influence behavior such as food and water
intake, social interaction, learning and cognitive function,
sexual behavior, sleep, and anhedonia (Larson and Dunn
2001). Comedication of schizophrenic patients with the
cyclo-oxygenase-2 inhibitor celecoxib showed greater
improvement in psychopathological scores than
antipsychotic treatment alone, suggesting that immune
dysfunction in schizophrenia is somehow linked to the
pathomechanisms of the disorder (Muller et al 2002). Thus,Neuropsychiatric Disease and Treatment 2005:1(2) 176
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increased IL-1β and IL-6 levels may be associated with
schizophrenia-related behavior. Further neurodevelopmental
animal studies could clarify the relationship between adult
cytokine levels and schizophrenia-associated behavior.
In summary, elevated IL-1β and IL-6 levels may be
related to chronic schizophrenia even in old age.
Confounding factors such as age, sex, smoking, and
antipsychotic medication have not been shown to affect these
serum cytokine levels. However, we have investigated only
a small sample size related to the quantity of confounding
variables, and correlations may become significant in a larger
sample. In addition, some factors such as additional
treatment with benzodiazepines or anticholinergic
medication have not been investigated. Further studies
should investigate cytokine expression in post-mortem
brains. To clarify the effect of neurodevelopmental
disturbances on immune function and schizophrenia-related
behavior, investigations of animal models are warranted.
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